Increased fracture risk represents an emerging and severe complication of diabetes. The
resulting prolonged immobility and hospitalisations can lead to substantial morbidity and …

Sclerostin is most recognized for its role in controlling bone formation but is also expressed
in the heart, aorta, coronary, and peripheral arteries. This review summarizes research on …

Bone contributes to supporting the body, protecting the central nervous system and other
organs, hematopoiesis, the regulation of mineral metabolism (mainly calcium and …

Introduction Atherosclerosis is the main pathological change in diabetic angiopathy, and
vascular inflammation plays an important role in early atherosclerosis. Extracellular heat …

Background Sclerostin is an inhibitor of the Wnt/b-catenin pathway, which regulates bone
formation, and can be expressed in vascular smooth muscle cells (VSMCs). Type 2 diabetes …

Diabetic kidney disease (DKD) causes the greatest proportion of end-stage renal disease
(ESRD)–related mortality and has become a high concern in patients with diabetes mellitus …

Introduction: Sclerostin is a glycoprotein known as a negative regulator of bone formation,
predominantly expressed by mature osteocytes. There is no causative evidence information …

Lipid and glucose metabolism are critical for human activities, and their disorders can cause
diabetes and obesity, two prevalent metabolic diseases. Studies suggest that the bone …

Background Bone-related proteins (such as sclerostin and osteoprotegerin [OPG]) are
involved in the development of atherosclerosis. However, the relationship between bone …

Background: Sclerostin, a regulator of bone metabolism and vascular calcification involved
in regulating the Wnt/β-catenin signaling pathway, has been shown to be involved in the …